Earlier Announced, Zevra Therapeutics To Acquire Acer Therapeutics Terms; Total Potential Value For Up To $91M, Consisting Of ~2.96M Shares Of Zevra Common Stock Valued At $15M And Up To An Additional $76M In A Series Of Potential Cash Payments
Portfolio Pulse from Happy Mohamed
Zevra Therapeutics has announced its plans to acquire Acer Therapeutics. The total potential value of the deal is up to $91M, which includes approximately 2.96M shares of Zevra common stock valued at $15M and up to an additional $76M in a series of potential cash payments.
August 31, 2023 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Acer Therapeutics is being acquired by Zevra Therapeutics in a deal potentially worth up to $91M. This includes 2.96M shares of Zevra stock and up to $76M in cash payments.
Acquisitions often lead to a short-term increase in the stock price of the company being acquired. In this case, Acer Therapeutics is being acquired by Zevra Therapeutics, which could lead to a short-term increase in Acer's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100